Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R, Reubenson G, Davies MA, Coovadia A.

Pediatr Infect Dis J. 2013 Aug;32(8):851-5. doi: 10.1097/INF.0b013e31828c3738.

2.

Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.

Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, Rabie H, Wood R, Cox V, Vizcaya LS, Muchiri E, Davies MA; IeDEA Southern Africa Paediatric Collaboration.

Pediatr Infect Dis J. 2014 Jun;33(6):617-22. doi: 10.1097/INF.0000000000000222.

3.

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.

Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V; MONOD Study Group.

BMC Med. 2017 Apr 24;15(1):85. doi: 10.1186/s12916-017-0842-4.

4.

A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.

Cassim H, Otwombe K, Lazarus E, Liberty A, Gray GE, Greeff OBW, Violari A.

PLoS One. 2017 Jul 7;12(7):e0180645. doi: 10.1371/journal.pone.0180645. eCollection 2017.

5.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
6.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
7.

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.

J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.

8.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams.

AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20.

9.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e.

10.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R.

AIDS. 2007 Jan 30;21(3):325-33.

PMID:
17255739
11.

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.

Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Säll C, Sönnerborg A, Tunbäck P, Gisslén M.

AIDS Res Hum Retroviruses. 2010 May;26(5):533-40. doi: 10.1089/aid.2009.0177.

PMID:
20455766
12.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356
13.

Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.

Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):535-41. doi: 10.1097/QAI.0000000000000071.

14.

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, Davis EA, Shaefer M; ESS40013 Study Team.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):257-64.

PMID:
15980684
15.

Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ.

PLoS One. 2013;8(1):e55111. doi: 10.1371/journal.pone.0055111. Epub 2013 Jan 25.

16.

First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04.

Antivir Ther. 2007;12(3):317-24.

PMID:
17591021
17.

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.

PMID:
25934146
18.

Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.

HIV Clin Trials. 2009 Mar-Apr;10(2):76-87. doi: 10.1310/hct1002-76.

PMID:
19487177
19.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
20.

Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.

Kang SJ, An JH, Kim J, Jang MO, Kim SE, Park KH, Jung SI, Jang HC.

Jpn J Infect Dis. 2013;66(4):317-9.

Supplemental Content

Support Center